GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Valuation Rank

Neurocrine Biosciences (BSP:N1BI34) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Neurocrine Biosciences Valuation Rank Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences (BSP:N1BI34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Valuation Rank
Comparable Companies
VTRS CTLT ITCI ELAN LNTH PRGO ALKS ALVO PBH AMPH ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ SZSE:000538 HKSE:03692 TSE:4507
Traded in Other Exchanges
NBIX:USA NB3:Germany
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Website
https://www.neurocrine.com
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.